July 28, 2025 a 07:43 pm
BLDR: Fundamental Ratio Analysis - Builders FirstSource, Inc.
Builders FirstSource, Inc. operates within the construction industry, offering building materials and services. Currently rated ‘A-’, the company shows strong fundamentals with particular strengths in discounted cash flow and return on equity. Overall, the stock reveals a mix of opportunities and challenges for interested investors.
Fundamental Ratings
Builders FirstSource, Inc. displays strong fundamental ratings within several categories.
| Category | Score | Visualization |
|---|---|---|
| Overall | 4 | |
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 3 | |
| Price to Book | 2 |
Historical Ratings
Comparison of historical rating data with the present indicates stability in the company's fundamentals.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-07-28 | 4 | 5 | 5 | 4 | 1 | 3 | 2 |
| Previous | 0 | 5 | 5 | 4 | 1 | 3 | 2 |
Analyst Price Targets
Current analysis of price targets from industry analysts shows a median target of $135, indicating a potential upside.
| High | Low | Median | Consensus |
|---|---|---|---|
| $155 | $130 | $135 | $140 |
Analyst Sentiments
The sentiment among analysts is predominantly positive, with a consensus rating of 'Buy'.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 25 | |
| Hold | 14 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Builders FirstSource, Inc. is a solid player in the construction sector with favourable fundamental ratios, making it an attractive option for value-focused investors. The positive analyst sentiment combined with substantial price target potential suggests notable growth opportunities. However, the relatively high debt-to-equity ratio may pose risks in a volatile market environment. Overall, the company’s strong return on investments and discounted cash flow scores highlight its operational efficacy.